Please assess the completion status of the following clinical trial:

Trial Title: Tolerability, Efficacy, and PK of ZSP1601 in Patients With Non-Alcoholic Steatohepatitis (NASH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects are required to meet the following criteria in order to be included in the trial:~  1. Signature signed informed consent before the trial, and fully understood the content, process and possible adverse reactions.~ 2. Subjects must be willing and able to adhere to the visit schedule and protocol requirements and be available to complete the study.~ 3. Subjects(including partners)have no gestation plans and must use reliable methods of contraception during the study and until 6 months following the last dose of investigational product.~ 4. Male and female subjects aged 18-65 (including 18 and 65).~ 5. B ultrasound confirmed fatty liver.~ 6. NASH diagnosis or NASH phenotypic diagnosis.~ 7. Liver fat ≥10% at baseline (MRI-PDFF)~Exclusion Criteria:~* Eligible subjects must not meet any of the following exclusion criteria:~  1. Excessive drinking for 3 consecutive months within 1 year before screening.~ 2. Allergic constitution.~ 3. Subjects who donated blood or bleeding profusely(\> 400 mL)in the 3 months preceding study screening.~ 4. Subjects having a history of bariatric surgery or preparing for bariatric surgery recently.~ 5. Subjects having a history of liver transplantation or plans for liver transplantation~ 6. Any diseases that increase the risk of bleeding, such as hemorrhoids, acute gastritis or gastric and duodenal ulcers.~ 7. Liver biopsy indicates cirrhosis or previous clinical diagnosis of cirrhosis.~ 8. Type 1 diabetes mellitus.~ 9. Uncontrolled type 2 diabetes mellitus (HbA1c≥8.0%)。~ 10. Any clinically significant abnormality upon physical examination or in the clinical laboratory tests, history or presence of other causes of liver disease,but not limited to above disorders: hepatitis b or hepatitis c virus (HCV) infection and chronic alcoholic liver disease, drug-induced liver disease, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, Wilson 's disease, alpha 1 - antitrypsin deficiency, liver, obvious abnormal liver function (ALT and AST acuity 5 x ULN or TBIL acuity 1.5 x ULN), etc.~ 11. Dysphagia or any medical history in gastrointestinal that interferes with the absorption of drugs.~ 12. History of having any special food(including dragon fruit,mango,grapefruit,etc.),strenuous exercises,or other factors may interfere with the absorption, distribution, metabolism, or excretion of drug within 2 weeks prior to screening.~ 13. Participated in another clinical research study and received any investigational products within 3 months prior to dosing.~ 14. Presence of clinically significant abnormalities in ECG or QTcB\>450ms in males,or QTcB\>470ms in females.~ 15. HIV positive.~ 16. Clinically significant nephropathy or renal dysfunction, blood creatinine \>1.5×ULN, eGFR\< 60 mL/min/1.73m2 \[calculation formula: Ccr:(140-age)× weight (kg) /0.818×Scr(mumol /L), female ×0.85\].~ 17. Platelet count \<100×109/L.~ 18. Antinuclear antibody (ANA) confirmed positive and clinically significant.~ 19. Abnormal TSH with clinical significance.~ 20. Female during pregnancy and lactation or positive serum pregnancy test.~ 21. Patients with contraindication of MRI scan.~ 22. Take any product contains alcohol within 24 hours prior to dosing.~ 23. Have chocolate, any food or beverage that contains caffeine or xanthine within 24 hours prior to dosing.~ 24. Positive for urine drug screening or history of substance abuse for a period of 5 consecutive years before screening.~ 25. Any acute illness or concomitant medication from screening to first dosing.~ 26. As judged by the researcher, it is not suitable to join the clinical researcher.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- ZSP1601-Dose 1 (Type: EXPERIMENTAL): ZSP1601-50mg once daily
- ZSP1601-Dose 2 (Type: EXPERIMENTAL): ZSP1601-50mg twice daily
- ZSP1601-Dose 3 (Type: EXPERIMENTAL): ZSP1601-100mg once daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete